07:28 AM EST, 01/15/2026 (MT Newswires) -- Becton, Dickinson ( BDX ) said Thursday the US Food and Drug Administration has granted 510(k) clearance for its EnCor EnCompass breast biopsy and tissue removal system.

The company said the multi-modality system allows clinicians to perform breast biopsy procedures across imaging platforms using one integrated system.

Becton, Dickinson ( BDX ) said it expects the system to be available from early 2026.